|
TFB2M expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.95430379948903E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.08800002340814E-09 |
| Normal-vs-Stage2 |
1.360800E-04 |
| Normal-vs-Stage3 |
3.28450000530722E-09 |
| Normal-vs-Stage4 |
1.62790003699342E-09 |
| Stage1-vs-Stage2 |
3.276000E-01 |
| Stage1-vs-Stage3 |
4.176600E-01 |
| Stage1-vs-Stage4 |
1.965220E-01 |
| Stage2-vs-Stage3 |
1.631580E-01 |
| Stage2-vs-Stage4 |
7.002400E-02 |
| Stage3-vs-Stage4 |
5.483600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.06099639763625E-11 |
| Normal-vs-AfricanAmerican |
3.821600E-04 |
| Normal-vs-Asian |
2.1305999964305E-08 |
| Caucasian-vs-AfricanAmerican |
3.792400E-01 |
| Caucasian-vs-Asian |
8.329000E-01 |
| AfricanAmerican-vs-Asian |
3.032000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60299999940605E-08 |
| Normal-vs-Female |
2.20570228748329E-11 |
| Male-vs-Female |
9.069000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.67209645708067E-11 |
| Normal-vs-Age(41-60Yrs) |
1.03319997002416E-09 |
| Normal-vs-Age(61-80Yrs) |
1.00820000004109E-06 |
| Normal-vs-Age(81-100Yrs) |
2.853700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.616800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.285200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.174800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.657400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.682000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.813800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.101910E-02 |
| Classical-VS-Follicular |
8.758300E-02 |
| Classical-VS-Other |
6.540400E-01 |
| Classical-VS-Normal |
1.93310034646288E-10 |
| Tall-VS-Follicular |
1.479480E-03 |
| Tall-VS-Other |
7.530600E-01 |
| Tall-VS-Normal |
1.02310382388282E-11 |
| Follicular-VS-Other |
3.860200E-01 |
| Follicular-VS-Normal |
1.357240E-04 |
| Other-VS-Normal |
3.664500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.03429997899696E-09 |
| Normal-vs-N1 |
2.33160000195909E-08 |
| N0-vs-N1 |
9.989600E-02 |
|
|
